E2F-1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53-independent apoptosis - PubMed (original) (raw)

E2F-1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53-independent apoptosis

J Nip et al. Mol Cell Biol. 1997 Mar.

Abstract

Mutations in the retinoblastoma (pRb) tumor suppressor pathway including its cyclin-cdk regulatory kinases, or cdk inhibitors, are a hallmark of most cancers and allow unrestrained E2F-1 transcription factor activity, which leads to unregulated G1-to-S-phase cell cycle progression. Moderate levels of E2F-1 overexpression are tolerated in interleukin 3 (IL-3)-dependent 32D.3 myeloid progenitor cells, yet this induces apoptosis when these cells are deprived of IL-3. However, when E2F activity is augmented by coexpression of its heterodimeric partner, DP-1, the effects of survival factors are abrogated. To determine whether enforced E2F-1 expression selectively sensitizes cells to cytotoxic agents, we examined the effects of chemotherapeutic agents and radiation used in cancer therapy. E2F-1 overexpression in the myeloid cells preferentially sensitized cells to apoptosis when they were treated with the topoisomerase II inhibitor etoposide. Although E2F-1 alone induces moderate levels of p53 and treatment with drugs markedly increased p53, the deleterious effects of etoposide in E2F-1-overexpressing cells were independent of p53 accumulation. Coexpression of Bcl-2 and E2F-1 in 32D.3 cells protected them from etoposide-mediated apoptosis. However, Bcl-2 also prevented apoptosis of these cells upon exposure to 5-fluorouracil and doxorubicin, which were also cytotoxic for control cells. Pretreating E2F-1-expressing cells with ICRF-193, a second topoisomerase II inhibitor that does not damage DNA, protected the cells from etoposide-induced apoptosis. However, ICRF-193 cooperated with DNA-damaging agents to induce apoptosis. Therefore, topoisomerase II inhibition and DNA damage can cooperate to selectively induce p53-independent apoptosis in cells that have unregulated E2F-1 activity resulting from mutations in the pRb pathway.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Cell. 1991 Jun 14;65(6):1053-61 - PubMed
    1. Proc Natl Acad Sci U S A. 1994 Mar 1;91(5):1781-5 - PubMed
    1. Cell. 1991 Jun 28;65(7):1243-53 - PubMed
    1. Science. 1991 Nov 22;254(5035):1138-46 - PubMed
    1. Nature. 1992 Jan 9;355(6356):176-9 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources